Scientists in Sergiu Pasca's group at Stanford University have used patient-derived organoids, assembloids and in vivo transplantation to discover and validate an antisense oligonucleotide drug for the treatment of Timothy syndrome.
Aging is one of the leading causes that is associated with brain dysfunction, degeneration, and disease. Progressive inflammation in the brain due to age adversely affects brain function and increases susceptibility to neurodegenerative diseases like Alzheimer's disease.
Creating human brain progenitors and neurons from human pluripotent stem cells (hPSCs) offers vast possibilities to study, model and treat neurological and neurodegenerative diseases, which are among the most intractable diseases that afflict our society.
Stanford inventors have developed a multiomic methodology for identifying and measuring non-structural proteins and RNA species from human hair. This approach will reveal unique biomarker profiles for wellness or diseases that are not currently identified.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Stanford inventors have developed a method to create spatially micropatterned vascularized structures that enable in vitro representation of human and animal biology in models such as cells, tissues, organs, and organoids.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Researchers in the Lee lab have discovered a totally novel approach to restore the impairment of empathy associated with many neurological disorders and mental illnesses.
A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.